Century Therapeutics Inc (IPSC): Forecast Levels Chart

Century Therapeutics (IPSC) relies on external contractors for vector creation and testing, utilizing cloud services to scale its research. The company is a pioneer in developing off-the-shelf immune cells via iPSC technologies with immense R&D potential. The current figure stands at 5.13. This chart of the market valuation demonstrates a dependence on external financing due to the absence of stable operating profit and commercial products.

Century Tx (IPSC): Analyst Consensus Forecast from 07/04/2022 to 11/11/2026

Metric breakdowns and analytics for Century Therapeutics (IPSC)

- price and consensus price forecast:

Market Chart centurytx.com|IPSC - Price Target Chart

- stock exchange capitalization data:

Market Valuation Century Therapeutics Inc|IPSC - Total Company Value

- balance sheet net asset value indicators:

Net Assets per Share Century Therapeutics|IPSC - Book Capitalization|Market Cap to Net Assets Ratio centurytx.com|IPSC - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

IPSC - Company Net Income|Expected Net Profit Century Therapeutics|IPSC - P/E Multiple|Forward Price to Earnings Multiple centurytx.com|IPSC - Price/Earnings to Growth Multiple|Company Value to EBITDA Century Therapeutics Inc|IPSC - Operating profit before deduction of amortization|Earnings per share for the trailing year Century Therapeutics|IPSC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months centurytx.com|IPSC - Earnings growth in current year|Expected net earnings per share growth next year Century Therapeutics

General company analysis:IPSC (Century Tx)

An objective valuation of Century Therapeutics (IPSC) requires a fundamental fair value analysis, where the median analyst target price serves as a weighted average forecast of the asset's future value by professional experts. This indicator measures market capitalization expectations, while the price chart confirms the value of the proprietary iPSC gene-editing platform and its competitive advantages in tumor therapy.

Competitors of Century Therapeutics